118 related articles for article (PubMed ID: 31058544)
1. Dietary Glycemic Index and Glycemic Load and Risk of Breast Cancer by Molecular Subtype in Mexican Women.
Guerrero CH; Gamboa-Loira B; Mérida-Ortega Á; López-Carrillo L
Nutr Cancer; 2019; 71(8):1283-1289. PubMed ID: 31058544
[TBL] [Abstract][Full Text] [Related]
2. Dietary Patterns and Breast Cancer Risk in Women from Northern Mexico.
Flores-García MK; Mérida-Ortega Á; Denova-Gutiérrez E; López-Carrillo L
Nutr Cancer; 2021; 73(11-12):2763-2773. PubMed ID: 33356597
[TBL] [Abstract][Full Text] [Related]
3. A cumulative index of exposure to endogenous estrogens and breast cancer by molecular subtypes in northern Mexican women.
Rojas-Lima E; Gamboa-Loira B; Cebrián ME; Rothenberg SJ; López-Carrillo L
Breast Cancer Res Treat; 2020 Apr; 180(3):791-800. PubMed ID: 32086656
[TBL] [Abstract][Full Text] [Related]
4. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.
Ellingjord-Dale M; Vos L; Tretli S; Hofvind S; Dos-Santos-Silva I; Ursin G
Breast Cancer Res; 2017 Jan; 19(1):10. PubMed ID: 28114999
[TBL] [Abstract][Full Text] [Related]
5. Breast MRI background parenchymal enhancement as an imaging bridge to molecular cancer sub-type.
Dilorenzo G; Telegrafo M; La Forgia D; Stabile Ianora AA; Moschetta M
Eur J Radiol; 2019 Apr; 113():148-152. PubMed ID: 30927939
[TBL] [Abstract][Full Text] [Related]
6. Dietary glycemic index and glycemic load and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC).
Romieu I; Ferrari P; Rinaldi S; Slimani N; Jenab M; Olsen A; Tjonneland A; Overvad K; Boutron-Ruault MC; Lajous M; Kaaks R; Teucher B; Boeing H; Trichopoulou A; Naska A; Vasilopoulo E; Sacerdote C; Tumino R; Masala G; Sieri S; Panico S; Bueno-de-Mesquita HB; Van-der-A D; van Gils CH; Peeters PH; Lund E; Skeie G; Asli LA; Rodriguez L; Navarro C; Amiano P; Sanchez MJ; Barricarte A; Buckland G; Sonestedt E; Wirfält E; Hallmans G; Johansson I; Key TJ; Allen NE; Khaw KT; Wareham NJ; Norat T; Riboli E; Clavel-Chapelon F
Am J Clin Nutr; 2012 Aug; 96(2):345-55. PubMed ID: 22760570
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
[TBL] [Abstract][Full Text] [Related]
9. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
10. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
Kobayashi N; Hikichi M; Ushimado K; Sugioka A; Kiriyama Y; Kuroda M; Utsumi T
Clin Transl Oncol; 2017 Oct; 19(10):1232-1240. PubMed ID: 28409323
[TBL] [Abstract][Full Text] [Related]
11. Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.
Subramaniam S; Bhoo-Pathy N; Taib NA; Tan GH; See MH; Jamaris S; Ho GF; Looi LM; Yip CH
World J Surg; 2015 Oct; 39(10):2450-8. PubMed ID: 26138872
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer risk factors in relation to molecular subtypes in breast cancer patients from Kenya.
Sayed S; Fan S; Moloo Z; Wasike R; Bird P; Saleh M; Shaikh AJ; Figueroa JD; Naidoo R; Makokha FW; Gardner K; Oigara R; Njoroge FW; Magangane P; Mutebi M; Chauhan R; Mwanzi S; Govender D; Yang XR
Breast Cancer Res; 2021 Jun; 23(1):68. PubMed ID: 34174935
[TBL] [Abstract][Full Text] [Related]
14. The Association between ER, PR, HER2, and ER-/PR+ Expression and Lung Cancer Subsequent in Breast Cancer Patients: A Retrospective Cohort Study Based on SEER Database.
Shao HY; Hao BT; Gao FX
Breast J; 2023; 2023():7028189. PubMed ID: 38021219
[TBL] [Abstract][Full Text] [Related]
15. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
[TBL] [Abstract][Full Text] [Related]
16. Correlation between Ki67 and histological grade in breast cancer patients treated with preoperative chemotherapy.
Petric M; Martinez S; Acevedo F; Oddo D; Artigas R; Camus M; Sanchez C
Asian Pac J Cancer Prev; 2014; 15(23):10277-80. PubMed ID: 25556461
[TBL] [Abstract][Full Text] [Related]
17. Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients.
Effi AB; Aman NA; Koui BS; Koffi KD; Traore ZC; Kouyate M
Asian Pac J Cancer Prev; 2016; 17(4):1973-8. PubMed ID: 27221883
[TBL] [Abstract][Full Text] [Related]
18. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA; Bauer KR; Brown MM; Caggiano V
Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa.
Hadgu E; Seifu D; Tigneh W; Bokretsion Y; Bekele A; Abebe M; Sollie T; Merajver SD; Karlsson C; Karlsson MG
BMC Womens Health; 2018 Feb; 18(1):40. PubMed ID: 29444670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
